Advertisement
U.S. markets closed

Adicet Bio, Inc. (ACET)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.9500-0.0500 (-2.50%)
At close: 04:00PM EDT
1.9500 0.00 (0.00%)
After hours: 05:39PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.0000
Open2.0100
Bid2.3500 x 1400
Ask2.5000 x 2200
Day's Range1.8800 - 2.0550
52 Week Range1.1000 - 7.5000
Volume919,655
Avg. Volume1,772,225
Market Cap159.998M
Beta (5Y Monthly)1.63
PE Ratio (TTM)N/A
EPS (TTM)-3.3500
Earnings DateMay 07, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.57
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ACET

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Adicet Bio, Inc.
    AAON: Lowering target price to $84.00AAON INC has an Investment Rating of HOLD; a target price of $84.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • Business Wire

    Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

    REDWOOD CITY, Calif. & BOSTON, March 11, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference being held March 26, 2024.

  • Business Wire

    Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif. & BOSTON, March 01, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on February 29, 2024.

  • Business Wire

    Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

    REDWOOD CITY, Calif. & BOSTON, February 05, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference being held from February 7-8, 2024 in New York.